– USA, CT – Biodel Inc., a specialty biopharmaceutical company, announced the appointment of Arlene M. Morris to its board of directors.
Ms. Morris was recently the President and CEO of Syndax, a Boston based epigenetic company. Previously, she was the president, chief executive officer and member of the board of directors of Affymax, Inc.
During her eight years at Affymax, Ms. Morris led the company through the development of OMONTYS peginesatide, a strategic collaboration with Takeda, an initial public offering, and several follow on offerings.
Prior to Affymax, Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counsels biopharmaceutical and biotechnology companies on strategic transactions.
Before that, she was the senior vice president of business development at Coulter Pharmaceuticals, Inc., where she completed numerous transactions including a merger between Corixa and Coulter.
She was also the vice president of business development at Scios where she completed numerous transactions. Ms. Morris began her career at Johnson & Johnson as a sales representative, rising to vice president of business development.
Ms. Morris serves on the board of directors of Neovacs SA and the Medical University of South Carolina Foundation for Research and Development. She received her bachelor’s degree in biology from Carlow College.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.